Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

Gina Li; Nicolas Bonamici; Mahua Dey; Maciej S. Lesniak; Irina V. Balyasnikova

doi:10.1080/17425247.2018.1378642

Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

Gina Li, Nicolas Bonamici, Mahua Dey, Maciej S. Lesniak, Irina V. Balyasnikova^*

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Review article › peer-review

41 Scopus citations

Abstract

Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

Original language	English (US)
Pages (from-to)	163-172
Number of pages	10
Journal	Expert Opinion on Drug Delivery
Volume	15
Issue number	2
DOIs	https://doi.org/10.1080/17425247.2018.1378642
State	Published - Feb 1 2018

Funding

This paper was funded by the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, R01CA122930 (MSL) and NIH R01NS087990 (MSL, IVB) and K08NS092895 (MD). The authors would like to extend their gratitude to their medical illustrator, Michael Gallagher, for his contribution to this manuscript. This paper was funded by the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, R01CA122930 (MSL) and NIH R01NS087990 (MSL, IVB) and K08NS092895 (MD).

Keywords

CNS delivery
Glioblastoma
intranasal delivery
malignant glioma
stem cells

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/17425247.2018.1378642

Cite this

@article{eb09a62c2ef545e8811688553a98137e,

title = "Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies",

abstract = "Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.",

keywords = "CNS delivery, Glioblastoma, intranasal delivery, malignant glioma, stem cells",

author = "Gina Li and Nicolas Bonamici and Mahua Dey and Lesniak, {Maciej S.} and Balyasnikova, {Irina V.}",

note = "Publisher Copyright: {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = feb,

day = "1",

doi = "10.1080/17425247.2018.1378642",

language = "English (US)",

volume = "15",

pages = "163--172",

journal = "Expert Opinion on Drug Delivery",

issn = "1742-5247",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

AU - Li, Gina

AU - Bonamici, Nicolas

AU - Dey, Mahua

AU - Lesniak, Maciej S.

AU - Balyasnikova, Irina V.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

AB - Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

KW - CNS delivery

KW - Glioblastoma

KW - intranasal delivery

KW - malignant glioma

KW - stem cells

UR - http://www.scopus.com/inward/record.url?scp=85042556519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042556519&partnerID=8YFLogxK

U2 - 10.1080/17425247.2018.1378642

DO - 10.1080/17425247.2018.1378642

M3 - Review article

C2 - 28895435

AN - SCOPUS:85042556519

SN - 1742-5247

VL - 15

SP - 163

EP - 172

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

IS - 2

ER -

Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this